

Table S4: Individual Association of Change in Urine Protein and Clinical Outcomes

Study	Covariate unadjusted ^a Hazard Ratio (95% CI)	Covariate adjusted ^b Hazard Ratio (95% CI)
1	0.74 (0.67, 0.81)	0.76 (0.69, 0.84)
2	1.22 (0.83, 1.79)	1.21 (0.78, 1.88)
4	0.77 (0.63, 0.94)	0.80 (0.66, 0.97)
5	1.24 (0.83, 1.86)	1.39 (0.85, 2.27)
6	0.66 (0.42, 1.06)	0.73 (0.43, 1.23)
7	1.05 (0.68, 1.61)	0.95 (0.59, 1.52)
8	0.84 (0.59, 1.21)	0.77 (0.52, 1.14)
10	0.39 (0.24, 0.64)	0.35 (0.21, 0.60)
12	0.59 (0.46, 0.74)	0.58 (0.46, 0.74)
13	0.72 (0.65, 0.80)	0.71 (0.64, 0.79)
14	0.80 (0.60, 1.06)	0.61 (0.44, 0.84)
15	0.58 (0.52, 0.65)	0.62 (0.55, 0.69)
16	0.97 (0.80, 1.18)	0.97 (0.79, 1.18)
17	0.83 (0.59, 1.15)	0.67 (0.44, 1.04)
18	0.85 (0.69, 1.05)	0.83 (0.67, 1.02)
19	0.74 (0.61, 0.90)	0.76 (0.63, 0.92)
20	0.84 (0.57, 1.25)	0.93 (0.61, 1.42)
21	0.47 (0.30, 0.75)	0.36 (0.21, 0.61)
22	0.87 (0.67, 1.14)	0.84 (0.63, 1.11)
23	0.66 (0.49, 0.88)	0.90 (0.35, 2.34)
Total ^c	0.74 (0.67, 0.82)	0.74 (0.66, 0.82)

The clinical outcome includes ESRD, doubling of serum creatinine and death.

^aAdjusted for treatment, baseline Urine Protein, baseline Urine Protein x follow up time

^bAdjusted for Control for treatment: Baseline Urine Protein, Baseline Urine Protein x follow up time, Serum, creatinine, Age, Systolic Blood Pressure, and Sex. Urine protein was log transformed in statistical analyses.

^cShown is the overall pooled HR under a Bayesian mixed effects model and 95% Bayesian credible interval.